Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Biosimilar
25 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Biosimilars
FDA Statement on Low-Cost Biosimilar and Interchangeable Protein Products
PR-M12-19-NI-037
FDA Approval
Sandoz Receives FDA Approval for Oncology Supportive Care Biosimilar Ziextenzo™
PR-M11-19-NI-006
Biosimilar
Dr. Reddy's Laboratories Announces the Launch of Versavo® (bevacizumab biosimilar) in India
PR-M08-19-NI-063
Biosimilar
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab
PR-M07-19-NI-020
FDA Approval
Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)
PR-M07-19-NI-015
Biosimilar Approval
Herceptin Biosimilar Approved in the U.S.
PAO-M06-19-NI-017
Biosimilar
Successful Results Reported for Another Rituximab Biosimilar
PAO-M05-19-NI-020
Biosimilar
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
PR-M01-19-NI-079
Biosimilar
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
PR-M01-19-NI-002
Investment
US Tax Savings Help AbbVie
PAO-M11-18-NI-012
Biosimilars
Herceptin Biosimilar Gets Positive Opinion in Europe
PAO-M10-18-NI-024
FDA
Another Biosimilar Gets Nod from Independent FDA Panel
PAO-M10-18-NI-018
Biosimilars
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
PR-M10-18-NI-071
Biosimilars
Innovent Receives IND Approval to Initiate Clinical Trials in China with Sintilimab in Combination with its Biosimilar to Bevacizumab
PR-M10-18-NI-056
Biosimilars
U.S. Department of Veterans Affairs Signs Contract with Merck for its Remicade Biosimilar
PAO-M10-18-NI-010
Biosimilar
Legislation Introduced to Require Reporting of Biosimilar Agreements
PAO-M08-18-NI-020
Biosimilars
Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
PR-M06-18-NI-100
Biosimilars
Another mAb Biosimilar on the Horizon in Europe
PAO-M06-18-NI-006
Oncology
MSD Launches Herceptin Biosimilar in UK
PAO-M03-18-NI-015
Biosimilar
Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
PR-M03-18-NI-017
Biosimilars
Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®
PR-M01-18-NI-092
Regulatory
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
PR-M01-18-NI-060
FDA Guidance
FDA Received Numerous Comments on Its Draft Guidance for Evaluating Biosimilarity
PAO-M01-18-NI-004
Drug Development
Chinese Biopharma Receives Series A Financing
PAO-M12-17-NI-031
1
2
»
